How did GRI Bio's operating expenses trend in Q4 2024 compared to previous quarters?

GRI Bio's operating expenses showed a decreasing trend in Q4 2024 compared to the previous quarters. The company's net loss for Q4 2024 was $2.13 million, which is lower than the net loss of $2.44 million in the same period of 2023. This indicates a slight improvement in operational efficiency. 1. **Research and Development Expenses**: The research and development expenses for Q4 2024 were $1.13 million, which is slightly down from $1.89 million in Q3 2024. This decrease is primarily due to reduced personnel expenses. 2. **General and Administrative Expenses**: The general and administrative expenses for Q4 2024 were $1 million, which is a decrease from $1.25 million in Q3 2024. This reduction is mainly attributed to a decrease in stock-based compensation expenses. Overall, GRI Bio's operating expenses are trending downwards in Q4 2024 compared to the previous quarters, indicating a better financial performance and operational efficiency.